Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

Quarterly Focus on Hematology | CLL

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented.

In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL.


  • Prof. Arnon Kater, MD, PhD
    • Hematologist, Amsterdam UMC (AMC), The Netherlands
  • Prof. Stephan Stilgenbauer, MD
    • Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany
  • Gert Jan Timmers, MD, PhD
    • Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands
  • Prof. Paolo Ghia, MD, PhD
    • Internist, Università Vita-Salute San Raffaele, Milan, Italy
  • Kostas Stamatopoulos, MD, PhD
    • CERTH, Thessaloniki, Greece  

Publications to be discussed

  1. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018

  2. Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019

About our "Quarterly Focus" format

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

Related items

Congress news 08/12/2014

ASH 2014 Highlight 3 - Leukemia

Highlight on leukemia: Prof. Dr. med. Uwe Platzbecker tells if ATRA+arsenicumtrioxide should become the new standard care for non-high risk APML by illustrating the Italian-German APL0406 trial. Ian Flinn MD PhD provides an overview on novel therapies for CLL. Prof. Dr. Michele Baccarani discusses whether imatinib remains the standard therapy for CML by elaborating on the DASISION, SPIRIT-2 and EPIC trails. Prof. Dr. Rien van Oers concludes with the PROLONG trial which investigates ofatumumab maintenance therapy in R/R CLL.

Congress news 12/06/2014

EHA 2014 - News Report 1

EHA 2014 – News Report 1 on: CLL by Prof. Stephan Stilgenbauer, the José Carreras Lecture ‘Genetics to guide management of patients with AML by Prof. Hartmut Döhner, the pathophysiology of auto-immune hemolytic anemia by Prof. Hannah Tamary and Stem Cell Transplantation: focus on chronic GvHD by Prof William Arcese.

Congress news 14/12/2012

ASH 2012 | Hematology News Program 3

Third Hematology TV News Program from the ASH 2012 TPA-agonist romiplostim: can we reconsider its use in MDS? Have we arrived into the era of targeted therapy in CLL with ibrutinib? JAK-inhibition may be relevant for MPN beyond myelofibrosis

Congress news 16/06/2012

EHA 2012 | News Program 16/06/12

EHA 2012 Hematology TV News Program June 16 Myelodysplastic Syndromes Interview Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

Congress news 16/06/2012

EHA 2012 | News Program June 16

EHA 2012 Hematology TV News Program June 16. Myelodysplastic Syndromes Interview Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

Congress news 13/12/2018

EMUC 2018: POTOMAC & ALBAN trials

Dr. Evanguelos Xylinas, urologist at Cochin Hospital, Paris Descartes University (France), is chief editor of the bladder cancer section of the UROONCO educational platform and talks about the POTOMAC trial (durvalumab plus BCG vs. BCG) and the ALBAN trial (atezolizumab plus BCG vs. BCG).

Congress news 11/12/2018

ASH 2018: Highlights lymphoma

Dr. Martin Hutchings from Denmark talks about the first in-human trial he presented at ASH 2018 and mentions another congress highlight: the ECHELON-2 trial.